A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Idarubicin (Primary) ; Quizartinib (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
03 Nov 2023 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
26 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight